



PATENT APPLICATION

0360

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): KOSTENUIK et al.

Serial No.: 09/843,221

Group Art Unit No.:

Filed: April 26, 2001

Examiner:

For: MODULATORS OF RECEPTORS FOR  
PARATHYROID HORMONE AND PARATHYROID  
HORMONE-RELATED PROTEIN

Docket No.: A-665B

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gadi

Attorney for Applicants

Registration No.: 33,111

Phone: (805) 447-2688

Date: July 12, 2001

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

July 12, 2001  
Date

Christina A. Muterro  
Signature